2,4122,5714,8445,214Amortization of acquired intangible assets
1,0271,0842,0562,184Costs associated with legal proceedings
140-253-Resolution of molecular diagnostic distribution agreements
--7,000-Acquisition and severance costs
485453815524Income tax effect of above adjusting items
(520)(740)(1,055)(1,475)Adjusted net income
$7,239$6,320$15,097$12,926Adjusted net income per share, basic
$ 0.18$ 0.15$
.32Shares used in computing adjusted net income per share, basic
40,49741,06440,69340,992Adjusted net income per share, diluted
$ 0.17$ 0.15$
.31Shares used in computing adjusted net income per share, diluted
The Company makes reference in this release to "non-GAAP net income" which excludes the impact of costs associated with the ENZO Life Sciences, Inc. complaint discussed in the Legal Proceedings section of our 10-Q and certain other recurring and non-recurring expenses. The Company believes that excluding these items and their related tax effects from its financial results reflects operating results that are more indicative of the Company's ongoing operating performance while improving comparability to prior periods, and, as such may provide investors with an enhanced understanding of the Company's past financial performance and prospects for the future. This information is not intended to be considered in isolation or as a substitute for income from operations, net income, net income per share or expense information prepared in accordance with GAAP.
|SOURCE Luminex Corporation|
Copyright©2012 PR Newswire.
All rights reserved